Transparency matters because it gives plan sponsors a clearer view of what they are paying for. It can help employers understand unit costs, rebate value, contract terms, and where spending is concentrated. That kind of visibility makes it easier to ask better questions and compare options more effectively.

Still, transparency is only the starting point.

A plan can be transparent and still be expensive. It can offer clean reporting and still allow unnecessary utilization. It can show where costs are rising and still do little to slow the trend. Seeing the numbers is useful, but it is not the same as changing the outcome.

That distinction matters in pharmacy benefits because a large share of spend often comes from a small number of high-cost claims. Specialty medications now account for more than half of pharmacy spend in many employer plans, even though they are used by a small percentage of members. GLP-1s have also become a major driver of trend, especially when use extends beyond a plan’s intended coverage rules.

Transparency can reveal those patterns. It cannot correct them by itself.

The value of transparency is not just in making data visible. Its value is in helping employers make smarter decisions. A transparent pharmacy strategy should help answer questions like:

• Which drugs are driving the most spend?
• How much of total cost depends on rebate value?
• Where is utilization rising fastest?
• Which categories need tighter controls?
• Are current fulfillment channels delivering the lowest net cost?

Those answers can point a plan in the right direction. But the next step requires action.

Pharmacy cost problems are rarely caused by one issue. They are usually driven by a mix of factors: inappropriate utilization, weak prior authorization criteria, poor channel strategy, missed biosimilar opportunities, and lack of alignment between plan design and actual member behavior.

Transparency can help uncover those issues. It does not solve them.

That is why employers should treat transparency as a foundation, not a finish line. If the goal is lower trend and better long-term plan performance, visibility must be paired with stronger management.

If transparency shows where the waste is, clinical management is what helps remove it.

This is the most important lever in pharmacy benefits because the costliest drug is often the one that should not have been approved in the first place. Once an avoidable high-cost claim enters the plan, it is hard to recover that spend through pricing changes alone.

Strong clinical management helps make sure each prescription aligns with medical necessity, evidence-based care, and the plan’s rules. It moves a pharmacy benefit from passive payment to active oversight.

Many of the fastest-growing drug categories require close management. GLP-1s are a clear example. These therapies can deliver meaningful clinical value, but they can also create major cost exposure when plans do not tightly manage eligibility, diagnosis alignment, and ongoing use.

For employers, the challenge is not simply that GLP-1 utilization is rising. The challenge is that spending can rise quickly when use extends beyond covered indications or when controls are too loose to catch misuse early.

The same pattern can show up in other categories too, including specialty drugs, off-label prescribing, and certain branded medications where lower-cost options may be appropriate.

A strong clinical management program should do more than check boxes. It should actively guide decisions at the point where cost and care meet. That includes:

• Tight prior authorization criteria
• Evidence-based reviews for medical necessity
• Monitoring for continued appropriateness of therapy
• Clear enforcement of plan coverage rules
• Step therapy when clinically appropriate
• Support for lower-cost alternatives, including generics and biosimilars

These tools help reduce waste without lowering the quality of care. In many cases, they also improve the member experience by encouraging safer, more appropriate treatment pathways.

Clinical programs work best when decisions are grounded in evidence rather than volume incentives. If drug approval decisions are influenced by parties that benefit from higher utilization, cost control becomes harder.

Independent clinical oversight can help create better alignment. It supports decisions based on safety, appropriateness, and plan design instead of financial interest in a specific product or dispensing route.

That matters because pharmacy trend is often built over time, one approval at a time. Small patterns become major cost problems if no one steps in early.

This is the point many pharmacy benefit discussions miss. Employers often spend too much time asking whether a plan is transparent and not enough time asking whether the plan has the right controls in place.

Transparency can tell you what happened. Clinical management helps determine what should happen next.

That is why it is the real engine behind sustainable savings.

Even the best reporting and strongest clinical oversight will fall short if a plan cannot execute on lowest net cost.

This third pillar is about putting the right drug in the right channel at the right cost. That includes smart use of generics, biosimilars, alternative fulfillment options, and channel optimization across the plan.

The goal is simple: do not just chase the lowest visible price. Focus on the lowest net cost.

A drug may look cheaper in one channel at the point of sale, but that does not always mean the plan is saving money overall. Net cost can be affected by several factors, including rebate value, dispensing fees, member disruption, and the availability of lower-cost therapeutic alternatives.

That is why execution matters. Plans need flexibility to evaluate medications one by one and choose the most cost-effective path based on the full picture.

Two of the clearest opportunities for savings are generics and biosimilars.

Generic drugs have long been a key cost-control tool, but there is still room for improvement when plans fail to guide members toward them consistently. Biosimilars are also becoming more important, especially in categories with high specialty spend. When clinically appropriate, they can lower costs without sacrificing outcomes.

But those savings do not happen automatically. Plans need the right formulary strategy, provider communication, and utilization controls to make those options stick.

Channel strategy is another major part of lowest net cost execution. For some drugs, traditional pharmacy networks may still make sense. For others, alternative fulfillment options may offer better value.

The key is flexibility.

A strong pharmacy strategy should make it possible to:

• Use standard channels where they remain cost-effective

• Direct select drugs to lower-cost fulfillment options

• Preserve visibility across all channels

• Maintain the same clinical standards regardless of where a prescription is filled

That modular approach helps plans adapt as the market changes. It also reduces the risk of overcommitting to a single model that may not work equally well across every drug category.

This pillar only works when pricing, clinical controls, and fulfillment strategy are aligned. If one area is weak, savings can slip away.

For example, a plan may identify a lower-cost biosimilar opportunity, but without the right prior authorization logic or formulary support, utilization may never shift. Or a plan may add a lower-cost channel, but if member communication is poor, adoption may stay low.

Execution is where strategy meets operations. It is also where a lot of savings are either captured or lost.

Employers do not need more noise around pharmacy benefits. They need a clearer framework for making decisions.

That framework starts with three questions:

1. Do we have enough transparency to see what is driving cost?
2. Do we have strong enough clinical management to prevent unnecessary spend?
3. Do we have the flexibility to execute toward the lowest net cost?

If the answer to any of those questions is no, there is likely room to improve plan performance.

A more strategic approach begins with evaluating pharmacy strategy across these three pillars.

1. Strengthen transparency where it supports decisions:

Look beyond basic reporting. Focus on visibility into cost drivers, rebate value, drug mix, specialty trend, and channel performance.

2. Audit clinical management programs:

Consider where generics, biosimilars, lower-cost channels, and targeted guidance can reduce total spend without creating unnecessary disruption for members.

Transparency is important. But it is not a standalone solution to the pharmacy benefits challenge.

Real savings come from pairing visibility with disciplined clinical management and a flexible strategy built around lowest net cost execution. Those are the three pillars that matter most.

When benefits advisors focus on all three, they are in a much stronger position to help employers reduce waste, manage trend, and build a pharmacy benefit that works better for both the plan and its members.